Default company panoramic image
121a9a95 9a52 49d3 802e 55c15b5ed377

Proteocyte Diagnostics Inc.

Proteocyte commercializes a novel molecular diagnostic test that accurately detects oral cancer before it happens to save lives and reduce health care costs.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Toronto, ON, Canada
  • Currency CAD
  • Founded August 2011
  • Employees 6
  • Website proteocyte.com

Company Summary

Proteocyte commercializes Straticyte a molecular diagnostic test that accurately detects oral cancer before it happens to save lives and save health care costs.
Straticyte predicts the probability of a precancerous lesion becoming cancer in the next 5 years based on the presence of biomarkers present in the lesions.
There are 3 million precancerous lesions each year, offering an addressable market of $900 million in the more developed world.

Team

  • Default avatar
    Ken Pritzker
    Chief Executive Officer

    Former Head, Pathology and Lab Medicine at Mount Sinai Hospital in Toronto, Dr. Pritzker is an internationally recognized leader in molecular cancer diagnostics.

  • Default avatar
    John Jordan
    Chief Financial Officer

    Financial executive with over 15 years working with entrepreneurs to create and build companies in financial and medical technology sectors.

  • Default avatar
    Ranju Ralhan
    Chief Scientific Officer

    Professor, Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Senior Scientist, Mount Sinai Hospital. Dr. Ralhan has received numerous international awards for work on cancer biomarkers.

  • Default avatar
    Mario Thomas
    President

    Formerly with Johnson & Johnson, Biochem Pharma, TerraGen Discovery, Entomed, T2C2 Bio Venture Capital and OCE. Mario has over 25 years of international experience in commercializing and financing of medical technologies.